Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib- sensitivetyrosine kinases

Michael C. Heinrich, Heikki Joensuu, George D. Demetri, Christopher L. Corless, Jane Apperley, Jonathan A. Fletcher, Denis Soulieres, Stephan Dirnhofer, Amy Harlow, Ajia Town, Arin McKinley, Shane G. Supple, John Seymour, Lilla Di Scala, Allan Van Oosterom, Richard Herrmann, Zariana Nikolova, Grant McArthur

Research output: Contribution to journalArticlepeer-review

139 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib- sensitivetyrosine kinases'. Together they form a unique fingerprint.

Medicine & Life Sciences